Immune checkpoint inhibitors have revolutionized the field of oncology, providing a novel
mechanism for anticancer therapy. Programmed death 1--targeting antibodies …

Bladder cancer is the sixth most common cancer in the US and most tumors have urothelial
(transitional cell) histology. Platinum-based chemotherapy has long been the standard of …

Introduction: The efficacy of immune checkpoint inhibitors has been shown in many
malignancies. Urothelial cancers have a high mutational load and also express a high level …

Physicians have been enlivened by the first major breakthrough in over 30 years in
metastatic urothelial cancer (UC) with the approval of five new therapeutics involved in …

Metastatic urothelial cancer is an aggressive disease associated with a poor prognosis. In
the first-line setting, platinum-based chemotherapy is the standard of care but resistance …

Bladder cancer is the most common malignancy involving the genitourinary system (Siegel
et al. in CA Cancer J Clin, 66: 7–30, 2016). In the USA, it is the fifth most common cancer …

Immune checkpoint inhibitors are associated with durable and well-tolerated responses in
metastatic urothelial carcinoma. Predicting which patients respond to therapy has been …

Cancer of the urothelium is the sixth most common cancer in the United States and is seen
predominantly in men. Most cases of this disease present as non–muscle-invasive bladder …

Five new PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of
metastatic urothelial carcinoma (UC): pembrolizumab, atezolizumab, durvalumab …

The most prevalent pathological subtype of bladder and upper urinary tract malignancy is
urothelial carcinoma (UC). Traditional therapies mainly include surgical resection …